XLenti
Designação definitivamente arquivada
Marca Nominativa depositada no INPI em
20/09/2021 por Oxford Genetics Ltd,
processo nº 501628657, nas classes 01, 05, 42.
O processo não está mais ativo — o nome pode estar livre para novo pedido.
| Número do processo | 501628657 |
|---|
| Situação | Designação definitivamente arquivada |
|---|
| Apresentação | Nominativa |
|---|
| Natureza | Madri
Produto/Serviço |
|---|
| Data do depósito | 20/09/2021 |
|---|
| Data da concessão | — |
|---|
| Vigência até | 20/09/2021 |
|---|
| Titular | Oxford Genetics Ltd |
|---|
| CNPJ/CPF do titular | — |
|---|
| UF · País | — · GB |
|---|
Classes e especificação
Chemical and biological substances for use in science and industry; nucleic acids; nucleic recombinant acids, synthetic deoxyribonucleic acids; chemical and biological reagents for non-medical purposes; chemical and biological reagents for scientific and research purposes; human and animal cells and parts thereof for non-medical purposes; microorganisms for non-medical purposes; human and animal cells and parts thereof for scientific and research purposes; microorganisms for scientific and research purposes; viral vectors for use in science and industry; lentiviruses, lentivirus particles and lentivirus plasmids, all for scientific and research purposes.;
Chemical and biological reagents for medical and veterinary use; diagnostic and test reagents for medical and veterinary use; human and animal cells and parts thereof for medical and veterinary purposes; microorganisms for medical and veterinary purposes; viral vectors for medical and veterinary purposes; lentiviruses, lentivirus particles and lentivirus plasmids, all for medical and veterinary use.;
Design services relating to the creation and alteration of chemical and biological reagents; design services relating to the creation and alteration of nucleic recombinant acids and synthetic deoxyribonucleic acids; design services relating to the creation and alteration of recombinant viruses; design services relating to the creation and alteration of lentiviruses, lentivirus particles and lentivirus plasmids; research, development and bioengineering services relating to lentiviruses; drug discovery services; design services relating to the creation and alteration of cell lines, elementary cells and parts thereof; design services relating to the creation and alteration of viral vectors; information and advice relating to all the aforesaid services.;